KALA BIO, Inc.

KALA BIO, Inc.

3.83
USD
-0.33
(-8.02%)
-3.33EPS
1.00BMarket Cap

Total Valuation

USD

As of June 30, 2026, KALA BIO, Inc. carries a market capitalization of 1.00B, placing it among publicly traded companies globally. Its enterprise value stands at 996.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.00B
Enterprise Value996.51M

Important Dates

KALA BIO, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of June 30, 2026, KALA BIO, Inc. has 19.34M shares outstanding.

Shares Outstanding19.34M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio110.98
P/TBV Ratio110.98
P/FCF Ratio-7.91
P/OCF Ratio-7.91

Financial Position

As of June 30, 2026, KALA BIO, Inc. maintains a current ratio of 6.88, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities.

Current Ratio6.88
Quick Ratio4.84
Interest Coverage-18.85

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -43.23, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 14.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-43.23
Employee Count14.00

Stock Price Statistics

USD

As of the close on November 16, 2026, KALA BIO, Inc.'s stock has declined approximately 99.64% over the past 52 weeks. The 50-day moving average sits at 9.74, while the 200-day moving average is 155.55.

52-Week Price Change-99.64%
50-Day Moving Average9.74
200-Day Moving Average155.55

Income Statement

USD

Over the twelve months ended June 30, 2026, KALA BIO, Inc. generated - - in revenue and converted that into -10.08M in net income, yielding earnings per share of -3.33. EBITDA reached -20.80M, while operating income came in at -23.93M.

Operating Income-23.93M
Pretax Income-10.08M
Net Income-10.08M
EBITDA-20.80M
EBIT-20.99M
Earnings Per Share (EPS)-3.33

Balance Sheet

USD

These figures are as of June 30, 2026. Total book value stands at 9.04M, with working capital of 9.04M providing operational flexibility.

Cash & Cash Equivalents7.23M
Net Debt-229,000.00
Equity (Book Value)9.04M
Book Value Per Share0.47
Working Capital9.04M

Cash Flow

USD

KALA BIO, Inc. produced -19.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting 1,000.00 in capital expenditures, free cash flow totaled -19.86M - equivalent to -6.56 per share.

Operating Cash Flow-19.86M
Capital Expenditures1,000.00
Free Cash Flow-19.86M
FCF Per Share-6.56

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.48, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KALA BIO, Inc. shareholders.

Shareholder Yield0.48
FCF Yield-12.64

Stock Splits

KALA BIO, Inc.'s most recent stock split took place on November 16, 2026 with a 30:1 split ratio.

Last Split Date11/16/2026
Split Ratio30:1

Scores

As of June 30, 2026, KALA BIO, Inc. has an Altman Z-Score of 292.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score292.78